

Arthur J Matas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2374222/publications.pdf>

Version: 2024-02-01

394
papers

21,686
citations

8732

75
h-index

12558

132
g-index

400
all docs

400
docs citations

400
times ranked

11434
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of Kidney Donors With Impaired Fasting Glucose. <i>Transplantation</i> , 2022, 106, 138-146.	0.5	7
2	Premature Death in Kidney Transplant Recipients: The Time for Trials is Now. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 665-673.	3.0	4
3	Nondirected, Advanced, and Voucher-Based Donation—The Importance of Terminology. <i>JAMA Surgery</i> , 2022, 157, 280.	2.2	1
4	Pre-kidney Donation Pregnancy Complications and Long-term Outcomes. <i>Transplantation</i> , 2022, Publish Ahead of Print, .	0.5	4
5	A regulated system of incentives for living kidney donation: Clearing the way for an informed assessment. <i>American Journal of Transplantation</i> , 2022, 22, 2509-2514.	2.6	5
6	iHFTA and chronic active T cell-mediated rejection: A tale of 2 (DeKAF) cohorts. <i>American Journal of Transplantation</i> , 2021, 21, 1866-1877.	2.6	16
7	The family voucher program: A 50-year simulation. <i>American Journal of Transplantation</i> , 2021, 21, 1350-1351.	2.6	1
8	Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1035-1044.	1.0	3
9	Risk of kidney disease after living kidney donation. <i>Nature Reviews Nephrology</i> , 2021, 17, 509-510.	4.1	2
10	Risk Prediction for Delayed Allograft Function. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	0.5	0
11	Outcomes of Living Kidney Donor Candidate Evaluations in the Living Donor Collective Pilot Registry. <i>Transplantation Direct</i> , 2021, 7, e689.	0.8	16
12	Early Steroid Cessation After Kidney Transplant. <i>JAMA Surgery</i> , 2021, 156, 314.	2.2	2
13	Incidence, risk factors, and long-term outcomes associated with antibody-mediated rejection—The long-term Deterioration of Kidney Allograft Function (DeKAF) prospective cohort study. <i>Clinical Transplantation</i> , 2021, 35, e14337.	0.8	6
14	Outcomes of Hypertensive Kidney Donors Using Current and Past Hypertension Definitions. <i>Kidney International Reports</i> , 2021, 6, 1242-1253.	0.4	7
15	Outcomes of Kidney Allograft and Recipient Survival After Liver Transplantation by Induction Type in the United States. <i>Liver Transplantation</i> , 2021, 27, 1553-1562.	1.3	3
16	Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1387-1397.	2.2	13
17	Novel Phenotypes for Acute Kidney Transplant Rejection Using Semi-Supervised Clustering. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2387-2388.	3.0	0
18	A Regulated System of Incentives for Kidney Donation—Time for a Trial!. <i>JAMA Surgery</i> , 2021, 156, 807.	2.2	2

#	ARTICLE	IF	CITATIONS
19	Intermediate Renal Outcomes, Kidney Failure, and Mortality in Obese Kidney Donors. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2933-2947.	3.0	7
20	Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial. <i>American Journal of Transplantation</i> , 2020, 20, 1039-1055.	2.6	39
21	Rapid discontinuation of prednisone in kidney transplant recipients from at-risk subgroups: an OPTN/SRTR analysis. <i>Transplant International</i> , 2020, 33, 181-201.	0.8	5
22	Induction type and outcomes for kidney graft and patient survival in recipients with prior lung transplantation in the United States. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 157-164.	0.3	3
23	Comparing Pretransplant and Posttransplant Outcomes When Choosing a Transplant Center: Focus Groups and a Randomized Survey. <i>Transplantation</i> , 2020, 104, 201-210.	0.5	8
24	Late Graft Loss After Kidney Transplantation: Is "Death With Function" Really Death With a Functioning Allograft?. <i>Transplantation</i> , 2020, 104, 1483-1490.	0.5	27
25	Pharmacogenomics in kidney transplant recipients and potential for integration into practice. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1457-1465.	0.7	3
26	Pediatric retransplantation of the liver: A prognostic scoring tool. <i>Pediatric Transplantation</i> , 2020, 24, e13775.	0.5	1
27	Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2020, 2020, 1-12.	0.7	0
28	Predictors of Survival After Liver Transplantation in Patients With the Highest Acuity (MELD ≥ 40). <i>Annals of Surgery</i> , 2020, 272, 458-466.	2.1	11
29	Enteric Conversion of Bladder-drained Pancreas as a Predictor of Outcomes in Almost 600 Recipients at a Single Center. <i>Transplantation Direct</i> , 2020, 6, e550.	0.8	4
30	Long-Term Living Kidney Donor Risk: A Web-Based Calculator. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2968-2969.	3.0	11
31	Organ Donation After Euthanasia. <i>JAMA Surgery</i> , 2020, 155, 924.	2.2	1
32	Re-hospitalization after pediatric kidney transplant: A single-center study. <i>Pediatric Transplantation</i> , 2020, 24, e13717.	0.5	4
33	End-stage Renal Disease After Kidney Donation—More Research Needed. <i>JAMA Surgery</i> , 2020, 155, e195473.	2.2	1
34	Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 766-769.	2.3	46
35	Inflammation in areas of fibrosis: The DeKAF prospective cohort. <i>American Journal of Transplantation</i> , 2020, 20, 2509-2521.	2.6	18
36	Development of a Patient-specific Search of Transplant Program Outcomes and Characteristics: Feedback From Kidney Transplant Patients. <i>Transplantation Direct</i> , 2020, 6, e585.	0.8	6

#	ARTICLE	IF	CITATIONS
37	Correlation of Glomerular Size With Donor-recipient Factors and With Response to Injury. Transplantation, 2020, Publish Ahead of Print, 2451-2460.	0.5	2
38	The Relationships Between Cold Ischemia Time, Kidney Transplant Length of Stay, and Transplant-related Costs. Transplantation, 2019, 103, 401-411.	0.5	43
39	Financial burden associated with time to return to work after living kidney donation. American Journal of Transplantation, 2019, 19, 204-207.	2.6	12
40	Medication adherence is associated with an increased risk of cancer in kidney transplant recipients: a cohort study. Nephrology Dialysis Transplantation, 2019, 34, 364-370.	0.4	8
41	Long-term outcomes of pediatric kidney transplant recipients with a pretransplant malignancy. Pediatric Transplantation, 2019, 23, e13557.	0.5	6
42	Prednisone-free maintenance immunosuppression in obese kidney transplant recipients. Clinical Transplantation, 2019, 33, e13668.	0.8	7
43	Kidney donor outcomes 50 years after donation. Clinical Transplantation, 2019, 33, e13657.	0.8	11
44	Larger nephron size, low nephron number, and nephrosclerosis on biopsy as predictors of kidney function after donating a kidney. American Journal of Transplantation, 2019, 19, 1989-1998.	2.6	39
45	Delivery of transplant care among Hmong kidney transplant recipients: Outcomes from a single institution. Clinical Transplantation, 2019, 33, e13539.	0.8	2
46	The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population. American Journal of Transplantation, 2019, 19, 2262-2273.	2.6	13
47	How patients choose kidney transplant centers: A qualitative study of patient experiences. Clinical Transplantation, 2019, 33, e13523.	0.8	18
48	Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups. American Journal of Transplantation, 2019, 19, 2795-2804.	2.6	35
49	Decision support needs of kidney transplant candidates regarding the deceased donor waiting list: A qualitative study and conceptual framework. Clinical Transplantation, 2019, 33, e13530.	0.8	23
50	Influence of the procurement surgeon on transplanted abdominal organ outcomes: An SRTR analysis to evaluate regional organ procurement collaboration. American Journal of Transplantation, 2019, 19, 2219-2231.	2.6	15
51	Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies. Transplantation, 2019, 103, 1131-1139.	0.5	17
52	Analysis of 75 Candidate SNPs Associated With Acute Rejection in Kidney Transplant Recipients: Validation of rs2910164 in MicroRNA MIR146A. Transplantation, 2019, 103, 1591-1602.	0.5	16
53	Molecular phenotype of kidney transplant indication biopsies with inflammation in scarred areas. American Journal of Transplantation, 2019, 19, 1356-1370.	2.6	41
54	Long-term psychosocial outcomes after nondirected donation: A single-center experience. American Journal of Transplantation, 2019, 19, 1498-1506.	2.6	12

#	ARTICLE	IF	CITATIONS
55	Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing. <i>Pharmacogenomics Journal</i> , 2019, 19, 375-389.	0.9	11
56	Long-term follow-up of the DeKAF cross-sectional cohort study. <i>American Journal of Transplantation</i> , 2019, 19, 1432-1443.	2.6	20
57	Hypertension after kidney donation: Incidence, predictors, and correlates. <i>American Journal of Transplantation</i> , 2018, 18, 2534-2543.	2.6	47
58	Measured Glomerular Filtration Rate After Kidney Donation: No Evidence of Accelerated Decay. <i>Transplantation</i> , 2018, 102, 1756-1761.	0.5	9
59	NPHP1 (Nephrocystin-1) Gene Deletions Cause Adult-Onset ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1772-1779.	3.0	74
60	Causes and timing of end-stage renal disease after living kidney donation. <i>American Journal of Transplantation</i> , 2018, 18, 1140-1150.	2.6	58
61	Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. <i>Pharmacogenomics</i> , 2018, 19, 175-184.	0.6	23
62	Gender Disparities and Financial Barriers to Living Kidney Donation. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1081-1083.	3.0	12
63	The clinical implications of the unique glomerular complement deposition pattern in transplant glomerulopathy. <i>Journal of Nephrology</i> , 2018, 31, 157-164.	0.9	1
64	GFR 25 years postdonation in living kidney donors with (vs. without) a first-degree relative with ESRD. <i>American Journal of Transplantation</i> , 2018, 18, 625-631.	2.6	29
65	Improved Outcomes of Kidney Transplantation in Infants (Age < 2 years). <i>Transplantation</i> , 2018, 102, 284-290.	0.5	17
66	Late graft failure after kidney transplantation as the consequence of late versus early events. <i>American Journal of Transplantation</i> , 2018, 18, 1158-1167.	2.6	39
67	Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2018, 4, e379.	0.8	84
68	Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. <i>Clinical Transplantation</i> , 2018, 32, e13424.	0.8	30
69	Incidence and magnitude of post-transplant cardiovascular disease after pediatric kidney transplantation: Risk factor analysis of 1058 pediatric kidney transplants at the university of Minnesota. <i>Pediatric Transplantation</i> , 2018, 22, e13283.	0.5	8
70	Implications of excess weight on kidney donation: Long-term consequences of donor nephrectomy in obese donors. <i>Surgery</i> , 2018, 164, 1071-1076.	1.0	31
71	Weight gain after kidney donation: Association with increased risks of type 2 diabetes and hypertension. <i>Clinical Transplantation</i> , 2018, 32, e13360.	0.8	19
72	Age alone is not a contraindication to kidney donation: Outcomes of donor nephrectomy in the elderly. <i>Clinical Transplantation</i> , 2018, 32, e13287.	0.8	13

#	ARTICLE	IF	CITATIONS
73	Return to normal activities and work after living donor laparoscopic nephrectomy. <i>Clinical Transplantation</i> , 2017, 31, e12862.	0.8	8
74	Cell-Free DNA and Active Rejection in Kidney Allografts. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2221-2232.	3.0	365
75	Living donor kidney allograft survival at 50 years. <i>Clinical Transplantation</i> , 2017, 31, e12938.	0.8	3
76	Outcomes and Risk Factors for Graft Loss: Lessons Learned from 1,056 Pediatric Kidney Transplants at the University of Minnesota. <i>Journal of the American College of Surgeons</i> , 2017, 224, 473-486.	0.2	38
77	A Case-Based Analysis of Whether Living Related Donors Listed for Transplant Share ESRD Causes with Their Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 663-668.	2.2	22
78	Rapid Discontinuation of Prednisone in Kidney Transplant Recipients. <i>Transplantation</i> , 2017, 101, 2590-2598.	0.5	28
79	Post-Transplant Malignancy after Pediatric Kidney Transplantation: Retrospective Analysis of Incidence and Risk Factors in 884 Patients Receiving Transplants Between 1963 and 2015 at the University of Minnesota. <i>Journal of the American College of Surgeons</i> , 2017, 225, 181-193.	0.2	17
80	Infection rates in tacrolimus versus cyclosporine-treated pediatric kidney transplant recipients on a rapid discontinuation of prednisone protocol: 1-year analysis. <i>Pediatric Transplantation</i> , 2017, 21, e12919.	0.5	14
81	Transplantation of solid organ recipients shedding Epstein-Barr virus <sc>DNA</sc> pre-transplant: A prospective study. <i>Clinical Transplantation</i> , 2017, 31, e13116.	0.8	6
82	Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3353-3362.	3.0	204
83	Financial Burden Borne by Laparoscopic Living Kidney Donors. <i>Transplantation</i> , 2017, 101, 2253-2257.	0.5	17
84	Concepts of Genomics in Kidney Transplantation. <i>Current Transplantation Reports</i> , 2017, 4, 116-123.	0.9	4
85	Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications. <i>Journal of Applied Laboratory Medicine</i> , 2017, 2, 309-321.	0.6	59
86	Long-term Outcomes for Living Pancreas Donors in the Modern Era. <i>Transplantation</i> , 2016, 100, 1322-1328.	0.5	34
87	Evolution of Living Donor Nephrectomy at a Single Center. <i>Transplantation</i> , 2016, 100, 1299-1305.	0.5	47
88	Ethical review of the responsibilities of the patient advocate in living donor liver transplant. <i>Clinical Liver Disease</i> , 2016, 7, 57-59.	1.0	4
89	Risk Factors for Developing Adult Cardiovascular Disease in Children Who Received a Kidney Transplant: Analysis of 1,055 Kidney Transplants between 1963-2015 at a Single Institution. <i>Journal of the American College of Surgeons</i> , 2016, 223, S148-S149.	0.2	1
90	Increasing the use of available deceased donor kidneys. <i>Nature Reviews Urology</i> , 2016, 13, 500-501.	1.9	2

#	ARTICLE	IF	CITATIONS
91	Postâ€transplant blood transfusions and pediatric renal allograft outcomes. <i>Pediatric Transplantation</i> , 2016, 20, 939-945.	0.5	17
92	Renal Function Profile in White Kidney Donors: The First 4 Decades. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2885-2893.	3.0	106
93	Outcomes of kidney retransplantation in recipients with prior postâ€transplant lymphoproliferative disorder. <i>Clinical Transplantation</i> , 2016, 30, 60-65.	0.8	18
94	Longterm healthâ€related quality of life after living liver donation. <i>Liver Transplantation</i> , 2016, 22, 53-62.	1.3	41
95	Valganciclovir Administration to Kidney Donors to Reduce the Burden of Cytomegalovirus and Epstein-Barr Virus Transmission During Transplantation. <i>Transplantation</i> , 2015, 99, 1186-1191.	0.5	23
96	The Impact of Donor Viral Replication at Transplant on Recipient Infections Posttransplant. <i>Transplantation</i> , 2015, 99, 602-608.	0.5	25
97	Differentially Expressed Gene Transcripts Using RNA Sequencing from the Blood of Immunosuppressed Kidney Allograft Recipients. <i>PLoS ONE</i> , 2015, 10, e0125045.	1.1	20
98	Moving Beyond Minimization Trials in Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2898-2901.	3.0	8
99	Through a Glass Darkly. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 20-29.	3.0	112
100	The Rationale for Incentives for Living Donors: An International Perspective?. <i>Current Transplantation Reports</i> , 2015, 2, 44-51.	0.9	4
101	Multigene predictors of tacrolimus exposure in kidney transplant recipients. <i>Pharmacogenomics</i> , 2015, 16, 841-854.	0.6	31
102	Living Donor Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1659-1669.	2.2	76
103	Reassessing Medical Risk in Living Kidney Donors. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1017-1019.	3.0	23
104	Little effect of state policies on organ donation in the USA. <i>Nature Reviews Nephrology</i> , 2015, 11, 570-572.	4.1	4
105	Emotional and Financial Experiences of Kidney Donors over the Past 50 Years. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2221-2231.	2.2	72
106	Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1711-1720.	3.0	163
107	Quality of Life in Elderly Kidney Transplant Recipients. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 1877-1882.	1.3	36
108	Kidney donors at increased risk? Additional studies are needed. <i>Kidney International</i> , 2014, 86, 650.	2.6	8

#	ARTICLE	IF	CITATIONS
109	The high cost of organ transplant commercialism. <i>Kidney International</i> , 2014, 86, 858-859.	2.6	2
110	Low birthweight and risk of albuminuria in living kidney donors. <i>Clinical Transplantation</i> , 2014, 28, 361-367.	0.8	21
111	Medical outcomes of adolescent live kidney donors. <i>Pediatric Transplantation</i> , 2014, 18, 336-341.	0.5	8
112	The Role of Procurement Biopsies in Acceptance Decisions for Kidneys Retrieved for Transplant. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 562-571.	2.2	85
113	Uric Acid and Allograft Loss From Interstitial Fibrosis/Tubular Atrophy. <i>Transplantation</i> , 2014, 97, 1066-1071.	0.5	16
114	Kidney Donation and Risk of ESRD. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 92.	3.8	11
115	Comparison of Cystatin C and Creatinine-Based Equations for GFR Estimation After Living Kidney Donation. <i>Transplantation</i> , 2014, 98, 871-877.	0.5	21
116	The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure. <i>Kidney International</i> , 2014, 85, 404-415.	2.6	17
117	Cystatin C Enhances Glomerular Filtration Rate Estimating Equations in Kidney Transplant Recipients. <i>American Journal of Nephrology</i> , 2014, 39, 59-65.	1.4	10
118	A Regulated System of Incentives for Living Kidney Donation: It Is Time for Opposing Groups to Have a Meaningful Dialogue!. <i>American Journal of Transplantation</i> , 2014, 14, 1944-1945.	2.6	4
119	Increased ESRD and mortality risk for kidney donors?. <i>Nature Reviews Nephrology</i> , 2014, 10, 130-131.	4.1	9
120	Calcineurin inhibitors in HLA-identical living related donor kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 209-218.	0.4	19
121	Telomere Length of Recipients and Living Kidney Donors and Chronic Graft Dysfunction in Kidney Transplants. <i>Transplantation</i> , 2014, 97, 325-329.	0.5	18
122	Live Donor Transplantation. , 2014, , 75-84.		0
123	Selection of Controls in Kidney Donor Outcome Studies: An Admirable Effort. <i>American Journal of Kidney Diseases</i> , 2013, 61, 194-196.	2.1	5
124	The Unjustified Classification of Kidney Donors as Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1406-1413.	2.2	36
125	Angiotensin II Blockade in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 320-327.	3.0	93
126	Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics. <i>Transplant International</i> , 2013, 26, 982-989.	0.8	47

#	ARTICLE	IF	CITATIONS
127	The impact of <scp>C</scp>4d and microvascular inflammation before we knew them. Clinical Transplantation, 2013, 27, 388-396.	0.8	14
128	Antihypertensive pharmacotherapy and long-term outcomes in pediatric kidney transplantation. Clinical Transplantation, 2013, 27, 472-480.	0.8	22
129	Inflammation in the setting of chronic allograft dysfunction post-kidney transplant: phenotype and genotype. Clinical Transplantation, 2013, 27, 348-358.	0.8	14
130	Predictors of Graft Failure and Death in Elderly Kidney Transplant Recipients. Transplantation, 2013, 96, 1089-1096.	0.5	71
131	Ten-Year Outcome after Rapid Discontinuation of Prednisone in Adult Primary Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 494-503.	2.2	75
132	Antithymocyte Globulin Induction in Living Donor Renal Transplant Recipients. Transplantation, 2012, 94, 331-337.	0.5	32
133	Reply to "Genetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantation". Transplantation, 2012, 93, e41-e42.	0.5	8
134	Living Donation: The Global Perspective. Advances in Chronic Kidney Disease, 2012, 19, 269-275.	0.6	17
135	Validation of tacrolimus equation to predict troughs using genetic and clinical factors. Pharmacogenomics, 2012, 13, 1141-1147.	0.6	32
136	Genetic and Clinical Determinants of Early, Acute Calcineurin Inhibitor-Related Nephrotoxicity. Transplantation, 2012, 93, 624-631.	0.5	62
137	Incentives for Organ Donation: Proposed Standards for an Internationally Acceptable System. American Journal of Transplantation, 2012, 12, 306-312.	2.6	81
138	Validation of genetic variants associated with early acute rejection in kidney allograft transplantation. Clinical Transplantation, 2012, 26, 418-423.	0.8	9
139	Outcome of living kidney donors left with multiple renal arteries. Clinical Transplantation, 2012, 26, E7-11.	0.8	9
140	Graft loss due to recurrent disease in pediatric kidney transplant recipients on a rapid prednisone discontinuation protocol. Pediatric Transplantation, 2012, 16, 704-710.	0.5	9
141	Kidney donation and chronic kidney disease. Minnesota Medicine, 2012, 95, 55-7.	0.1	8
142	The case for a regulated system of incentives for living kidney donation. Annals of the Royal College of Surgeons of England, 2011, 93, 188-190.	0.3	3
143	Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium. Transplantation, 2011, 91, 300-308.	0.5	151
144	Recurrent Glomerulonephritis Under Rapid Discontinuation of Steroids. Transplantation, 2011, 91, 1386-1391.	0.5	41

#	ARTICLE	IF	CITATIONS
145	Genetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantation. <i>Transplantation</i> , 2011, 91, 309-316.	0.5	52
146	Media Appeals by Pediatric Patients for Living Donors and the Impact on a Transplant Center. <i>Transplantation</i> , 2011, 91, 593-596.	0.5	12
147	Consideration of Donor Age and Human Leukocyte Antigen Matching in the Setting of Multiple Potential Living Kidney Donors. <i>Transplantation</i> , 2011, 92, 70-75.	0.5	27
148	Steroid minimization for sirolimus-treated renal transplant recipients. <i>Clinical Transplantation</i> , 2011, 25, 457-467.	0.8	6
149	Validation of single nucleotide polymorphisms associated with acute rejection in kidney transplant recipients using a large multi-center cohort. <i>Transplant International</i> , 2011, 24, 1231-1238.	0.8	27
150	Chronic Progressive Calcineurin Nephrotoxicity: An Overstated Concept. <i>American Journal of Transplantation</i> , 2011, 11, 687-692.	2.6	55
151	Living Kidney Donor Follow-Up: State-of-the-Art and Future Directions, Conference Summary and Recommendations. <i>American Journal of Transplantation</i> , 2011, 11, 2561-2568.	2.6	91
152	Promotion of Altruistic Donation: A Reply. <i>Transplantation</i> , 2010, 89, 902-903.	0.5	3
153	Single-Nucleotide Polymorphisms, Acute Rejection, and Severity of Tubulitis in Kidney Transplantation, Accounting for Center-to-Center Variation. <i>Transplantation</i> , 2010, 90, 1401-1408.	0.5	37
154	Evidence for Antibody-Mediated Injury as a Major Determinant of Late Kidney Allograft Failure. <i>Transplantation</i> , 2010, 90, 68-74.	0.5	447
155	Optimal Cutoff Point for Immunoperoxidase Detection of C4d in the Renal Allograft: Results From a Multicenter Study. <i>Transplantation</i> , 2010, 90, 1099-1105.	0.5	10
156	Steroid-free Maintenance Immunosuppression and ABO-incompatible Transplantation. <i>Transplantation</i> , 2010, 89, 648-649.	0.5	4
157	The impact of cytomegalovirus infection 1 year after primary renal transplantation. <i>Clinical Transplantation</i> , 2010, 24, 572-577.	0.8	33
158	GFR-estimating models in kidney transplant recipients on a steroid-free regimen. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1653-1661.	0.4	40
159	A molecular classifier for predicting future graft loss in late kidney transplant biopsies. <i>Journal of Clinical Investigation</i> , 2010, 120, 1862-1872.	3.9	179
160	Appraisal of GFR-Estimating Equations Following Kidney Donation. <i>American Journal of Kidney Diseases</i> , 2009, 53, 1050-1058.	2.1	20
161	Minimization of steroids in kidney transplantation. <i>Transplant International</i> , 2009, 22, 38-48.	0.8	36
162	Pancreas after living donor kidney transplants in diabetic patients: impact on long-term kidney graft function. <i>Clinical Transplantation</i> , 2009, 23, 437-446.	0.8	88

#	ARTICLE	IF	CITATIONS
163	Long-Term Consequences of Kidney Donation. <i>New England Journal of Medicine</i> , 2009, 360, 459-469.	13.9	1,168
164	Incentives for organ donation in the United States: feasible alternative or forthcoming apocalypse?. <i>Current Opinion in Organ Transplantation</i> , 2009, 14, 140-146.	0.8	26
165	Pediatric Kidney Transplantation Using a Novel Protocol of Rapid (6-Day) Discontinuation of Prednisone: 2-Year Results. <i>Transplantation</i> , 2009, 88, 237-241.	0.5	53
166	Kidney Transplant Half-Life (t [1/2]) After Rapid Discontinuation of Prednisone. <i>Transplantation</i> , 2009, 87, 100-102.	0.5	10
167	Urinary Peptide Patterns in Native Kidneys and Kidney Allografts. <i>Transplantation</i> , 2009, 87, 1807-1813.	0.5	6
168	Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1047-1056.	0.8	43
169	Design of a regulated system of compensation for living kidney donors. <i>Clinical Transplantation</i> , 2008, 22, 378-384.	0.8	41
170	2202 Kidney Transplant Recipients with 10 Years of Graft Function: What Happens Next?. <i>American Journal of Transplantation</i> , 2008, 8, 2410-2419.	2.6	115
171	Steroid Elimination—Who, When, How?. <i>Transplantation Proceedings</i> , 2008, 40, S52-S56.	0.3	9
172	Should we pay donors to increase the supply of organs for transplantation? Yes. <i>BMJ: British Medical Journal</i> , 2008, 336, 1342-1342.	2.4	28
173	Pretransplant Donor-Specific and Non-Specific Immune Parameters Associated With Early Acute Rejection. <i>Transplantation</i> , 2008, 85, 462-470.	0.5	43
174	In defense of a regulated system of compensation for living donation. <i>Current Opinion in Organ Transplantation</i> , 2008, 13, 379-385.	0.8	75
175	Posttransplant Diabetes Mellitus and Acute Rejection: Impact on Kidney Transplant Outcome. <i>Transplantation</i> , 2008, 85, 338-343.	0.5	55
176	Ethics of Paid Living-Unrelated Donation. , 2008, , 417-429.		0
177	Long-Term Outcomes for the Donor. , 2008, , 87-100.		0
178	Resolved: In Minimizing Kidney Transplant Immunosuppression, Steroids Should Go before Calcineurin Inhibitors: Pro. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 3026-3030.	3.0	5
179	Stable Kidney Function in the Second Decade After Kidney Transplantation While on Cyclosporine-Based Immunosuppression. <i>Transplantation</i> , 2007, 83, 722-726.	0.5	19
180	Cystatin C Is Not Superior to Creatinine-Based Models in Estimating Glomerular Filtration Rate in Former Kidney Donors. <i>Transplantation</i> , 2007, 84, 1112-1117.	0.5	12

#	ARTICLE	IF	CITATIONS
181	Two Years Postconversion From a Prograf-Based Regimen to a Once-Daily Tacrolimus Extended-Release Formulation in Stable Kidney Transplant Recipients. <i>Transplantation</i> , 2007, 83, 1648-1651.	0.5	74
182	Do inherited hypercoagulable states play a role in thrombotic events affecting kidney/pancreas transplant recipients?. <i>Clinical Transplantation</i> , 2007, 21, 32-37.	0.8	28
183	Inhibition of the membrane attack complex of complement for induction of accommodation in the hamster-to-rat heart transplant model. <i>Xenotransplantation</i> , 2007, 14, 572-579.	1.6	22
184	Must All Living Donor Compensation Be Viewed as Valuable Consideration?. <i>American Journal of Transplantation</i> , 2007, 7, 1309-1310.	2.6	6
185	Perioperative outcomes of cardiac surgery in kidney and kidney+pancreas transplant recipients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 133, 1212-1219.	0.4	22
186	Steroid-free immunosuppression in kidney transplant recipients: the University of Minnesota experience. <i>Clinical Transplants</i> , 2007, , 43-50.	0.2	2
187	Graft Loss from Recurrent Glomerulonephritis Is Not Increased with a Rapid Steroid Discontinuation Protocol. <i>Transplantation</i> , 2006, 81, 214-219.	0.5	34
188	The Ethics Statement of the Vancouver Forum on the Live Lung, Liver, Pancreas, and Intestine Donor. <i>Transplantation</i> , 2006, 81, 1386-1387.	0.5	130
189	Living or deceased donor kidney transplants for candidates with significant extrarenal morbidity. <i>Clinical Transplantation</i> , 2006, 20, 346-350.	0.8	11
190	Risk factors for rising creatinine in renal allografts with 1 and 3+yr survival. <i>Clinical Transplantation</i> , 2006, 20, 667-672.	0.8	6
191	Death on the Kidney Waiting List—Good Candidates or Not?. <i>American Journal of Transplantation</i> , 2006, 6, 1953-1956.	2.6	12
192	Transplantation Using Marginal Living Donors. <i>American Journal of Kidney Diseases</i> , 2006, 47, 353-355.	2.1	28
193	Urinary \hat{I}^{22} -Microglobulin Is Associated With Acute Renal Allograft Rejection. <i>American Journal of Kidney Diseases</i> , 2006, 47, 898-904.	2.1	50
194	Why We Should Develop a Regulated System of Kidney Sales: A Call for Action!: Table 1.. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 1129-1132.	2.2	63
195	Thymoglobulin Versus ATGAM Induction Therapy in Pediatric Kidney Transplant Recipients: A Single-Center Report. <i>Transplantation</i> , 2005, 79, 958-963.	0.5	42
196	Persistent, Asymptomatic, Microscopic Hematuria in Prospective Kidney Donors. <i>Transplantation</i> , 2005, 80, 1425-1429.	0.5	37
197	Surgical Complications After Kidney Transplantation. <i>Seminars in Dialysis</i> , 2005, 18, 505-510.	0.7	146
198	A Multicenter Pilot Study of Early (4-Day) Steroid Cessation in Renal Transplant Recipients Under Simulect, Tacrolimus and Sirolimus. <i>American Journal of Transplantation</i> , 2005, 5, 157-166.	2.6	86

#	ARTICLE	IF	CITATIONS
199	Long-Term Deterioration of Kidney Allograft Function. American Journal of Transplantation, 2005, 5, 1405-1414.	2.6	107
200	A Prospective Randomized Trial of Steroid-Free Maintenance Regimens in Kidney Transplant Recipients-An Interim Analysis. American Journal of Transplantation, 2005, 5, 1529-1536.	2.6	99
201	Prednisone-Free Maintenance Immunosuppression-A 5-Year Experience. American Journal of Transplantation, 2005, 5, 2473-2478.	2.6	160
202	Patient-Initiated Request for Donation Information. AMA Journal of Ethics, 2005, 7, 589.	0.4	0
203	The Importance of Innovative Efforts to Increase Organ Donation. JAMA - Journal of the American Medical Association, 2005, 294, 1691.	3.8	14
204	Outcome at 3 Years with a Prednisone-Free Maintenance Regimen: A Single-Center Experience with 349 Kidney Transplant Recipients. American Journal of Transplantation, 2004, 4, 980-987.	2.6	93
205	Twenty-Two Nondirected Kidney Donors: An Update on a Single Center's Experience. American Journal of Transplantation, 2004, 4, 1110-1116.	2.6	101
206	Surrogate Markers for Long-Term Renal Allograft Survival. American Journal of Transplantation, 2004, 4, 1179-1183.	2.6	72
207	Payment for Living Kidney Donors (Vendors) Is Not an Abstract Ethical Discussion Occurring in a Vacuum. American Journal of Transplantation, 2004, 4, 1380-1381.	2.6	17
208	The Case for Living Kidney Sales: Rationale, Objections and Concerns. American Journal of Transplantation, 2004, 4, 2007-2017.	2.6	103
209	Plasma homocysteine levels in living kidney donors before and after uninephrectomy. Translational Research, 2004, 143, 340-343.	2.4	13
210	Payment for Living Donor (Vendor) Kidneys: A Cost-Effectiveness Analysis. American Journal of Transplantation, 2004, 4, 216-221.	2.6	201
211	Long-term Immunosuppression, Without Maintenance Prednisone, After Kidney Transplantation. Annals of Surgery, 2004, 240, 510-517.	2.1	84
212	Human Leukocyte Antigen Type as a Risk Factor for Nonmelanomatous Skin Cancer in Patients after Renal Transplantation. Transplantation, 2004, 78, 775-778.	0.5	12
213	Medication noncompliance: another iceberg's tip. Transplantation, 2004, 77, 776-778.	0.5	31
214	Rapid Discontinuation of Prednisone in Higher-Risk Kidney Transplant Recipients. Transplantation, 2004, 78, 1397-1399.	0.5	32
215	Diabetes Mellitus after Kidney Transplantation in the United States. American Journal of Transplantation, 2003, 3, 178-185.	2.6	1,121
216	Improved Scoring System to Assess Adult Donors For Cadaver Renal Transplantation. American Journal of Transplantation, 2003, 3, 715-721.	2.6	170

#	ARTICLE	IF	CITATIONS
217	Morbidity and Mortality After Living Kidney Donation, 1999-2001: Survey of United States Transplant Centers. American Journal of Transplantation, 2003, 3, 830-834.	2.6	302
218	What's New and What's Hot in Transplantation: Clinical Science ATC 2003. American Journal of Transplantation, 2003, 3, 1465-1473.	2.6	12
219	Determinants of quality of life changes among long-term cardiac transplant survivors: results from longitudinal data. Journal of Heart and Lung Transplantation, 2003, 22, 1157-1167.	0.3	20
220	WHY STUDY KIDNEY TRANSPLANT RISK FACTORS?. Transplantation, 2003, 75, 266-267.	0.5	1
221	Risks versus benefits of living kidney donation. Current Opinion in Organ Transplantation, 2003, 8, 155-159.	0.8	2
222	Predicting long-term kidney graft survival: can new trials be performed?1,2. Transplantation, 2003, 75, 1256-1259.	0.5	26
223	Positive remote crossmatch: impact on short-term and long-term outcome in cadaver renal transplantation. Transplantation, 2003, 75, 501-505.	0.5	26
224	THE HISTORY OF THE CONCEPT OF BRAIN DEATH AND ORGAN PRESERVATION. , 2003, , 64-75.		2
225	Morbidity and mortality after living kidney donation, 1999-2001: survey of United States transplant centers. American Journal of Transplantation, 2003, 3, 830-4.	2.6	188
226	Preemptive Kidney Transplantation: The Advantage and the Advantaged. Journal of the American Society of Nephrology: JASN, 2002, 13, 1358-1364.	3.0	424
227	What???s special about the ethics of living donors? Reply to Ross et al.. Transplantation, 2002, 74, 421-422.	0.5	10
228	The nondirected live-kidney donor: ethical considerations and practice guidelines. Transplantation, 2002, 74, 582-589.	0.5	123
229	Prevention of Post-transplant Cardiovascular Disease - Report and Recommendations of an Ad Hoc Group1. American Journal of Transplantation, 2002, 2, 491-500.	2.6	71
230	Morbidity from Congenital Hepatic Fibrosis after Renal Transplantation for Autosomal Recessive Polycystic Kidney Disease. American Journal of Transplantation, 2002, 2, 360-365.	2.6	67
231	Improved Late Graft Survival and Half-Lives in Pediatric Kidney Transplantation: A Single Center Experience. American Journal of Transplantation, 2002, 2, 939-945.	2.6	26
232	Long-Term (20-37â€fYears) Follow-Up of Living Kidney Donors. American Journal of Transplantation, 2002, 2, 959-964.	2.6	155
233	Life satisfaction and adverse effects in renal transplant recipients: a longitudinal analysis. Clinical Transplantation, 2002, 16, 113-121.	0.8	108
234	Predictors of renal function following lung or heart-lung transplantation. Kidney International, 2002, 61, 2228-2234.	2.6	98

#	ARTICLE	IF	CITATIONS
235	Five preventable causes of kidney graft loss in the 1990s: A single-center analysis1. <i>Kidney International</i> , 2002, 62, 704-714.	2.6	117
236	Proposed guidelines for re-evaluation of patients on the waiting list for renal cadaver transplantation1. <i>Transplantation</i> , 2002, 73, 811-812.	0.5	19
237	Pancreas after kidney transplants. <i>American Journal of Surgery</i> , 2001, 182, 155-161.	0.9	53
238	ARE WOUND COMPLICATIONS AFTER A KIDNEY TRANSPLANT MORE COMMON WITH MODERN IMMUNOSUPPRESSION?. <i>Transplantation</i> , 2001, 72, 1920-1923.	0.5	209
239	May-Thurner Syndrome in Renal Transplantation. <i>Transplantation</i> , 2001, 71, 698-702.	0.5	13
240	Lessons Learned From More Than 1,000 Pancreas Transplants at a Single Institution. <i>Annals of Surgery</i> , 2001, 233, 463-501.	2.1	576
241	2,500 Living Donor Kidney Transplants: A Single-Center Experience. <i>Annals of Surgery</i> , 2001, 234, 149-164.	2.1	194
242	Kidney retransplants after initial graft loss to vascular thrombosis. <i>Clinical Transplantation</i> , 2001, 15, 6-10.	0.8	35
243	Peri-operative cardiac morbidity in kidney transplant recipients: incidence and risk factors. <i>Clinical Transplantation</i> , 2001, 15, 154-158.	0.8	76
244	Kidney and pancreas transplantation without a crossmatch in select circumstances - it can be done. <i>Clinical Transplantation</i> , 2001, 15, 236-239.	0.8	5
245	Life satisfaction in renal transplant recipients: Preliminary results from the Transplant Learning Center. <i>American Journal of Kidney Diseases</i> , 2001, 38, 580-587.	2.1	58
246	Rapid Discontinuation of Steroids in Living Donor Kidney Transplantation: A Pilot Study. <i>American Journal of Transplantation</i> , 2001, 1, 278-283.	2.6	93
247	From First Principles - Tubulitis in Protocol Biopsies and Learning from History. <i>American Journal of Transplantation</i> , 2001, 1, 4-5.	2.6	21
248	Donor Scoring System for Cadaveric Renal Transplantation. <i>American Journal of Transplantation</i> , 2001, 1, 162-170.	2.6	82
249	Transplant Kidneys Sooner: Discard Fewer Kidneys. <i>American Journal of Transplantation</i> , 2001, 1, 301-304.	2.6	15
250	Donor Scoring System for Cadaveric Renal Transplantation. <i>American Journal of Transplantation</i> , 2001, 1, 162.	2.6	1
251	DONOR PARAMETERS PREDICT EARLY GRAFT OUTCOME AFTER CADAVERIC RENAL TRANSPLANTATION.. <i>Transplantation</i> , 2000, 69, S263.	0.5	0
252	IS THERE AN ASSOCIATION BETWEEN CYTOMEGALOVIRUS (CMV) AND RENAL ARTERY STENOSIS (RAS) IN KIDNEY TRANSPLANT RECIPIENTS?. <i>Transplantation</i> , 2000, 69, S386.	0.5	13

#	ARTICLE	IF	CITATIONS
253	PRE-EMPTIVE TRANSPLANTS FOR PATIENTS WITH RENAL FAILURE. <i>Transplantation</i> , 2000, 70, 625-631.	0.5	89
254	Long-term follow-up of living kidney donors. <i>Current Opinion in Organ Transplantation</i> , 2000, 5, 319-323.	0.8	4
255	Predicting clinical outcome in the elderly renal transplant recipient. <i>Kidney International</i> , 2000, 57, 2144-2150.	2.6	98
256	Iliac artery stenosis masquerading as diuretic resistant congestive heart failure. <i>Clinical Transplantation</i> , 2000, 14, 11-13.	0.8	6
257	Should I accept this kidney?. <i>Clinical Transplantation</i> , 2000, 14, 90-95.	0.8	28
258	Renal transplantation for Type II diabetic patients compared with Type I diabetic patients and patients over 50 years old: a single-center experience. <i>Clinical Transplantation</i> , 2000, 14, 226-234.	0.8	29
259	Impact of acute rejection on development of chronic rejection in pediatric renal transplant recipients. <i>Pediatric Transplantation</i> , 2000, 4, 92-99.	0.5	39
260	Nondirected Donation of Kidneys from Living Donors. <i>New England Journal of Medicine</i> , 2000, 343, 433-436.	13.9	155
261	IMMUNOLOGIC AND NONIMMUNOLOGIC FACTORS. <i>Transplantation</i> , 2000, 69, 54.	0.5	104
262	LIVING UNRELATED DONORS IN KIDNEY TRANSPLANTS. <i>Transplantation</i> , 2000, 69, 1942-1945.	0.5	55
263	CLINICAL DETERMINANTS OF MULTIPLE ACUTE REJECTION EPISODES IN KIDNEY TRANSPLANT RECIPIENTS ¹ . <i>Transplantation</i> , 2000, 69, 2357-2360.	0.5	63
264	INCREASED INCIDENCE OF CARDIAC COMPLICATIONS IN KIDNEY TRANSPLANT RECIPIENTS WITH CYTOMEGALOVIRUS DISEASE. <i>Transplantation</i> , 2000, 70, 310-313.	0.5	48
265	Noncompliance and late graft loss: Implications for long-term clinical studies. <i>Transplantation Reviews</i> , 1999, 13, 78-82.	1.2	4
266	Current thinking on chronic renal allograft rejection: Issues, concerns, and recommendations from a 1997 roundtable discussion. <i>American Journal of Kidney Diseases</i> , 1999, 33, 150-160.	2.1	119
267	Decreased Acute Rejection in Kidney Transplant Recipients Is Associated with Decreased Chronic Rejection. <i>Annals of Surgery</i> , 1999, 230, 493.	2.1	47
268	CYTOMEGALOVIRUS DISEASE RECURRENCE AFTER GANCICLOVIR TREATMENT IN KIDNEY AND KIDNEY-PANCREAS TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1999, 67, 94-97.	0.5	62
269	MOUSE-TO-RABBIT XENOTRANSPLANTATION. <i>Transplantation</i> , 1999, 67, 360-365.	0.5	11
270	IMPACT OF TRANSFUSIONS AND ACUTE REJECTION ON POSTTRANSPLANTATION DONOR ANTIGEN-SPECIFIC RESPONSES IN TWO STUDY POPULATIONS ^{1,2} . <i>Transplantation</i> , 1999, 67, 697-702.	0.5	12

#	ARTICLE	IF	CITATIONS
271	LONG-TERM FOLLOW-UP OF LIVING KIDNEY DONORS: QUALITY OF LIFE AFTER DONATION ¹ . Transplantation, 1999, 67, 717-721.	0.5	299
272	LIVING DONORS >55 YEARS. Transplantation, 1999, 67, 999-1004.	0.5	70
273	EVALUATION OF PRE- AND POSTTRANSPLANT DONOR-SPECIFIC TRANSFUSION/CYCLOSPORINE A IN NON-HLA IDENTICAL LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS. Transplantation, 1999, 68, 1117-1124.	0.5	20
274	FEATURES OF ACUTE REJECTION THAT INCREASE RISK FOR CHRONIC REJECTION ¹ . Transplantation, 1999, 68, 1200-1203.	0.5	84
275	IMMUNOLOGIC FACTORS: THE MAJOR RISK FOR DECREASED LONG-TERM RENAL ALLOGRAFT SURVIVAL ^{1,2} . Transplantation, 1999, 68, 1842-1846.	0.5	87
276	ASSOCIATION BETWEEN CYTOMEGALOVIRUS DISEASE AND CHRONIC REJECTION IN KIDNEY TRANSPLANT RECIPIENTS ¹ . Transplantation, 1999, 68, 1879-1883.	0.5	125
277	Reduced Cell Infiltration in Hearts from TNF- α or IL-1R knockout mice transplanted into rats.. Transplantation, 1999, 67, S554.	0.5	0
278	KIDNEY TRANSPLANT USING PEDIATRIC DONORS-EFFECT ON LONG TERM GRAFT AND PATIENT SURVIVAL RATES. Transplantation, 1999, 67, S575.	0.5	0
279	ADMINISTRATION OF OKT3 AS A TWO-HOUR INFUSION DOES NOT ATTENUATE FIRST-DOSE SIDE EFFECTS. Transplantation, 1999, 68, 709-710.	0.5	0
280	Risk factors for chronic rejection - a clinical perspective. Transplant Immunology, 1998, 6, 1-11.	0.6	38
281	Kidney Transplants From Living Donors: How Donation Affects Family Dynamics. Advances in Chronic Kidney Disease, 1998, 5, 89-97.	2.2	83
282	Kidney Transplantation in Children Younger Than 1 Year Using Cyclosporine Immunosuppression. Annals of Surgery, 1998, 228, 421-428.	2.1	15
283	KIDNEY TRANSPLANTATION WITHOUT A FINAL CROSSMATCH ^{1,2} . Transplantation, 1998, 66, 1835-1836.	0.5	12
284	Pretransplant Exposure to Donor HLA-DR Antigen in Random Transfusion Units and the Development of Donor Antigen-Specific Hyporeactivity. Human Immunology, 1997, 55, 148-153.	1.2	10
285	The role of monocytes and macrophages in delayed xenograft rejection. Xenotransplantation, 1997, 4, 40-48.	1.6	17
286	Risk factors for chronic rejection in pediatric renal transplant recipients - a single-center experience. Pediatric Nephrology, 1997, 11, 395-398.	0.9	34
287	Complications by age in primary pediatric renal transplant recipients. Pediatric Nephrology, 1997, 11, 399-403.	0.9	57
288	COMPLICATIONS AND RISKS OF LIVING DONOR NEPHRECTOMY ¹ . Transplantation, 1997, 64, 1124-1128.	0.5	231

#	ARTICLE	IF	CITATIONS
289	LIVING DONOR TRANSPLANTATION. , 1997, , 53-60.		0
290	Impact of age on renal graft survival in children after the first rejection episode. Pediatric Nephrology, 1996, 10, 474-478.	0.9	13
291	Combined liver and kidney transplantation. Transplant International, 1996, 9, 486-491.	0.8	20
292	GAS-GENERATING SYSTEMS IN ACUTE RENAL ALLOGRAFT REJECTION IN THE RAT. Transplantation, 1996, 61, 93-98.	0.5	71
293	EMPLOYMENT PATTERNS AFTER SUCCESSFUL KIDNEY TRANSPLANTATION1. Transplantation, 1996, 61, 729-733.	0.5	59
294	DELAYED ENDOCRINE PANCREAS GRAFT FUNCTION AFTER SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION. Transplantation, 1996, 61, 1323-1330.	0.5	68
295	DELAYED GRAFT FUNCTION IN THE ABSENCE OF REJECTION HAS NO LONG-TERM IMPACT. Transplantation, 1996, 61, 1331-1337.	0.5	150
296	ONE-YEAR FOLLOW-UP OF AN OPEN-LABEL TRIAL OF FK506 FOR PRIMARY KIDNEY TRANSPLANTATION1. Transplantation, 1996, 61, 1576-1581.	0.5	125
297	BABESIOSIS AND HEMOPHAGOCYTIC SYNDROME IN AN ASPLENIC RENAL TRANSPLANT RECIPIENT. Transplantation, 1996, 62, 537-539.	0.5	50
298	AN OPEN-LABEL, CONCENTRATION-RANGING TRIAL OF FK506 IN PRIMARY KIDNEY TRANSPLANTATION. Transplantation, 1996, 62, 900-905.	0.5	193
299	KIDNEY TRANSPLANT RECIPIENTS WHO DIE WITH FUNCTIONING GRAFTS. Transplantation, 1996, 62, 1029,1030.	0.5	57
300	PREGNANCY AFTER DONOR NEPHRECTOMY1,2. Transplantation, 1996, 62, 1934-1936.	0.5	41
301	Combined liver and kidney transplantation. Transplant International, 1996, 9, 486-491.	0.8	6
302	DELAYED GRAFT FUNCTION, ACUTE REJECTION, AND OUTCOME AFTER CADAVER RENAL TRANSPLANTATION. Transplantation, 1995, 59, 962-968.	0.5	455
303	CHRONIC RENAL ALLOGRAFT REJECTION IN THE FIRST 6 MONTHS POSTTRANSPLANT1,2. Transplantation, 1995, 60, 1413-1417.	0.5	16
304	ORGAN-SPECIFIC PATTERNS OF DONOR ANTIGEN-SPECIFIC HYPOREACTIVITY AND PERIPHERAL BLOOD ALLOGENEIC MICROCHIMERISM IN LUNG, KIDNEY, AND LIVER TRANSPLANT RECIPIENTS1. Transplantation, 1995, 60, 1546-1554.	0.5	66
305	Short- and Long-Term Outcomes of Kidney Transplants with Multiple Renal Arteries. Annals of Surgery, 1995, 221, 406-414.	2.1	135
306	The emergence of xenotransplantation. Transplant Immunology, 1995, 3, 21-31.	0.6	19

#	ARTICLE	IF	CITATIONS
307	Antibody Removal by Column Immunoabsorption Prevents Tissue Injury in an Ex Vivo Model of Pig-to-Human Xenograft Hyperacute Rejection. <i>Journal of Surgical Research</i> , 1995, 59, 43-50.	0.8	32
308	Renal transplantation. <i>Academic Radiology</i> , 1995, 2, 159-166.	1.3	9
309	RETRANSPLANTATION AFTER RENAL ALLOGRAFT LOSS DUE TO NONCOMPLIANCE ^{1,2} . <i>Transplantation</i> , 1995, 59, 467-471.	0.5	3
310	Beyond Hyperacute Rejection. <i>Transplantation</i> , 1995, 59, 171-176.	0.5	2
311	Removal Of Baboon And Human Antiporcine Igg And Igm Natural Antibodies By Immunoabsorption. <i>Transplantation</i> , 1995, 59, 294-299.	0.5	3
312	Causes of kidney allograft loss in a large pediatric population at a single center. <i>Pediatric Nephrology</i> , 1994, 8, 57-61.	0.9	26
313	Recurrence of steroid-resistant nephrotic syndrome in kidney transplants is associated with increased acute renal failure and acute rejection. <i>Kidney International</i> , 1994, 45, 1440-1445.	2.6	60
314	Cellular rejection in discordant xenografts when hyperacute rejection is prevented: analysis using adoptive and passive transfer. <i>Transplant Immunology</i> , 1994, 2, 87-93.	0.6	39
315	Pharmacokinetics of FK506 After Intravenous and Oral Administration in Patients Awaiting Renal Transplantation. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 859-864.	1.0	39
316	Renal Transplantation for Patients 60 Years of Age or Older A Single-Institution Experience. <i>Annals of Surgery</i> , 1994, 220, 445-460.	2.1	60
317	A PROSPECTIVE RANDOMIZED STUDY OF ACYCLOVIR VERSUS GANCICLOVIR PLUS HUMAN IMMUNE GLOBULIN PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION AFTER SOLID ORGAN TRANSPLANTATION ^{1,2} . <i>Transplantation</i> , 1994, 57, 876-883.	0.5	75
318	EVIDENCE THAT RAT XENOREACTIVE ANTIBODIES RECOGNIZE MULTIPLE PROTEIN ANTIGENS ON GUINEA PIG ENDOTHELIAL CELLS AND PLATELETS. <i>Transplantation</i> , 1994, 58, 458-466.	0.5	13
319	THE IMPACT OF THE QUALITY OF INITIAL GRAFT FUNCTION ON CADAVER KIDNEY TRANSPLANTS ^{1,2} . <i>Transplantation</i> , 1994, 57, 812-815.	0.5	123
320	ANTIBODY-MEDIATED REJECTION OF AN HLA-IDENTICAL, ABO-INCOMPATIBLE KIDNEY TRANSPLANT AFTER TWO FAILED CADAVER TRANSPLANTS. <i>Transplantation</i> , 1994, 58, 723-724.	0.5	0
321	Is MHC matching as a primary criterion in kidney allocation justified?. <i>Nature Genetics</i> , 1993, 5, 211-213.	9.4	2
322	Evolution of kidney, pancreas, and islet transplantation for patients with diabetes at the University of Minnesota. <i>American Journal of Surgery</i> , 1993, 166, 456-491.	0.9	118
323	Renal transplantation for infantile cystinosis: Long-term follow-up. <i>Journal of Pediatric Surgery</i> , 1993, 28, 232-238.	0.8	34
324	EVIDENCE THAT IMPROVED LATE RENAL TRANSPLANT OUTCOME CORRELATES WITH THE DEVELOPMENT OF IN VITRO DONOR ANTIGEN-SPECIFIC HYPOREACTIVITY. <i>Transplantation</i> , 1993, 55, 1017-1022.	0.5	79

#	ARTICLE	IF	CITATIONS
325	LRISK FACTORS FOR CHRONIC REJECTION IN RENAL ALLOGRAFT RECIPIENTS. Transplantation, 1993, 55, 752-756.	0.5	616
326	THE IMMUNOPATHOLOGY OF CARDIAC XENOGRAFT REJECTION IN THE GUINEA PIG-TO-RAT MODEL. Transplantation, 1993, 56, 1-8.	0.5	188
327	HALF-LIFE AND RISK FACTORS FOR KIDNEY TRANSPLANT OUTCOME—IMPORTANCE OF DEATH WITH FUNCTION. Transplantation, 1993, 55, 757-760.	0.5	78
328	EVIDENCE THAT 15-DEOXYSPERGUALIN INHIBITS NATURAL ANTIBODY PRODUCTION BUT FAILS TO PREVENT HYPERACUTE REJECTION IN A DISCORDANT XENOGRAFT MODEL. Transplantation, 1992, 54, 26-31.	0.5	53
329	MIZORIBINE PHARMACOKINETICS AND PHARMACODYNAMICS IN A CANINE RENAL ALLOGRAFT MODEL OF LOCAL IMMUNOSUPPRESSION ^{1,2} . Transplantation, 1992, 53, 12-19.	0.5	19
330	PEDIATRIC RENAL TRANSPLANTS—RESULTS WITH SEQUENTIAL IMMUNOSUPPRESSION ^{1,2} . Transplantation, 1992, 53, 46-51.	0.5	21
331	RECURRENCE OF DISEASE IN PATIENTS RETRANSPLANTED FOR FOCAL SEGMENTAL GLOMERULOSCLEROSIS. Transplantation, 1992, 53, 755-757.	0.5	57
332	CELL SUBSETS RESPONDING TO PURIFIED HEPATOCYTES AND EVIDENCE OF INDIRECT RECOGNITION OF HEPATOCYTE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I ANTIGEN. Transplantation, 1992, 53, 857-862.	0.5	16
333	CELL SUBSETS RESPONDING TO PURIFIED HEPATOCYTES AND EVIDENCE OF INDIRECT RECOGNITION OF HEPATOCYTE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I ANTIGEN. Transplantation, 1992, 53, 863-867.	0.5	22
334	THE IMPACT OF HLA MATCHING ON GRAFT SURVIVAL. Transplantation, 1992, 54, 568.	0.5	11
335	Pretransplant sensitization with major histocompatibility complex class I+ class II ⁺ hepatocytes leads to accelerated skin graft rejection. Journal of Surgical Research, 1992, 53, 182-187.	0.8	2
336	Simultaneous pancreas-kidney transplant versus kidney transplant alone in diabetic patients. Kidney International, 1992, 41, 924-929.	2.6	56
337	Outcome of renal transplantation or dialysis in patients with a history of renal cancer. Cancer, 1992, 70, 1564-1567.	2.0	8
338	IMMUNOPATHOLOGY OF HYPERACUTE XENOGRAFT REJECTION IN A SWINE-TO-PRIMATE MODEL. Transplantation, 1991, 52, 214-220.	0.5	418
339	TOTAL PANCREATECTOMY IN THE PIG FOR ISLET TRANSPLANTATION TECHNICAL ALTERNATIVES. Transplantation, 1991, 52, 11-14.	0.5	17
340	RISK FACTORS FOR SECOND RENAL ALLOGRAFTS IMMUNOSUPPRESSED WITH CYCLOSPORINE. Transplantation, 1991, 52, 253-258.	0.5	46
341	Causes of Renal Allograft Loss. Annals of Surgery, 1991, 214, 679-688.	2.1	162
342	PROGRESSION OF KIDNEY DISEASE IN CHRONIC RENAL TRANSPLANT REJECTION. Transplantation, 1991, 52, 239-243.	0.5	91

#	ARTICLE	IF	CITATIONS
343	ASSESSMENT OF RENAL FUNCTION IN TYPE I DIABETIC PATIENTS AFTER KIDNEY, PANCREAS, OR COMBINED KIDNEY-PANCREAS TRANSPLANTATION. <i>Transplantation</i> , 1991, 51, 1184-1189.	0.5	26
344	INTERACTION BETWEEN CYCLOSPORINE AND FLUCONAZOLE IN RENAL ALLOGRAFT RECIPIENTS. <i>Transplantation</i> , 1991, 51, 1014-1017.	0.5	104
345	A Unique Presentation of an Anastomotic Pseudoaneurysm-Case Report. <i>Vascular Surgery</i> , 1991, 25, 131-135.	0.3	1
346	EVIDENCE THAT ZERO ANTIGEN-MATCHED CYCLOSPORINE-TREATED RENAL TRANSPLANT RECIPIENTS HAVE GRAFT SURVIVAL EQUAL TO THAT OF MATCHED RECIPIENTS. <i>Transplantation</i> , 1990, 49, 332-336.	0.5	16
347	Renal Transplantation in Infants. <i>Annals of Surgery</i> , 1990, 212, 353-367.	2.1	87
348	THE USE OF CADAVER KIDNEYS FOR TRANSPLANTATION IN YOUNG CHILDREN. <i>Transplantation</i> , 1990, 50, 979-983.	0.5	14
349	COMPARISON OF IN VIVO AND IN VITRO IMMUNE RESPONSE TO PURIFIED HEPATOCYTES. <i>Transplantation</i> , 1990, 49, 429-435.	0.5	49
350	A NEW IN VITRO APPROACH TO DETERMINE ACQUIRED TOLERANCE IN LONG-TERM KIDNEY ALLOGRAFT RECIPIENTS. <i>Transplantation</i> , 1990, 50, 783-789.	0.5	35
351	Azathioprine Metabolism: Pharmacokinetics of 6-Mercaptopurine, 6-Thiouric Acid and 6-Thioguanine Nucleotides in Renal Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 358-363.	1.0	113
352	En bloc simultaneous pancreas and kidney allotransplantation in the pig. <i>Journal of Surgical Research</i> , 1990, 49, 366-370.	0.8	10
353	Role of macrophages in the immune response to hepatocytes. <i>Journal of Surgical Research</i> , 1990, 48, 568-572.	0.8	6
354	Liposomal formulation eliminates acute toxicity and pump incompatibility of parenteral cyclosporine. <i>Pharmaceutical Research</i> , 1989, 06, 601-607.	1.7	15
355	LOCAL IMMUNOSUPPRESSION WITH REDUCED SYSTEMIC TOXICITY IN A CANINE RENAL ALLOGRAFT MODEL. <i>Transplantation</i> , 1989, 48, 936-943.	0.5	21
356	LOCAL PREDNISOLONE INFUSION OF CANINE RENAL ALLOGRAFTS. <i>Transplantation</i> , 1989, 48, 1072-1074.	0.5	3
357	ALLOGRAFT RENAL VASCULAR THROMBOSIS-LACK OF INCREASE WITH CYCLOSPORINE IMMUNOSUPPRESSION. <i>Transplantation</i> , 1989, 47, 475-478.	0.5	58
358	SUCCESSFUL TRANSPLANTATION AFTER CONVERSION OF A POSITIVE CROSSMATCH TO NEGATIVE BY DISSOCIATION OF IgM ANTIBODY. <i>Transplantation</i> , 1989, 47, 127-129.	0.5	19
359	SUCCESSFUL TRANSPLANTATION OF HIGHLY SENSITIZED PATIENTS WITHOUT REGARD TO HLA MATCHING. <i>Transplantation</i> , 1988, 45, 338-341.	0.5	6
360	THE EFFECT OF THE REFERRING DIALYSIS CENTER ON RENAL TRANSPLANT RESULTS. <i>Transplantation</i> , 1988, 45, 894-898.	0.5	1

#	ARTICLE	IF	CITATIONS
361	ORGAN DONATION IN THREE MAJOR AMERICAN CITIES WITH LARGE LATINO AND BLACK POPULATIONS. Transplantation, 1988, 46, 553-557.	0.5	76
362	Timing of cyclosporine administration in patients with delayed graft function. Journal of Surgical Research, 1987, 43, 489-494.	0.8	7
363	Recurrent Membranoproliferative Glomerulonephritis Type 1 in Successive Renal Transplants. American Journal of Nephrology, 1987, 7, 143-149.	1.4	20
364	ALG TREATMENT OF STEROID-RESISTANT REJECTION IN PATIENTS RECEIVING CYCLOSPORINE. Transplantation, 1986, 41, 579-582.	0.5	29
365	TREATMENT OF RENAL TRANSPLANT REJECTION EPISODES IN PATIENTS RECEIVING PREDNISONE AND AZATHIOPRINE. Transplantation, 1985, 40, 35-38.	0.5	6
366	A Proposal for Cadaver Organ Procurement: Routine Removal with Right of Informed Refusal. Journal of Health Politics, Policy and Law, 1985, 10, 231-244.	0.9	18
367	Presumed consent for organ retrieval. Theoretical Medicine and Bioethics, 1984, 5, 155-166.	0.4	16
368	SUCCESSFUL KIDNEY TRANSPLANTATION WITH CURRENT-SERA-NEGATIVE/HISTORICAL-SERA-POSTIVE T CELL CROSSMATCH. Transplantation, 1984, 37, 111-112.	0.5	21
369	Cold storage preservation of islet and pancreas grafts as assessed by in vivo function after transplantation to diabetic hosts. Cryobiology, 1983, 20, 138-150.	0.3	10
370	The Value of Needle Renal Allograft Biopsy I. A Retrospective Study of Biopsies Performed During Putative Rejection Episodes. Annals of Surgery, 1983, 197, 226-237.	2.1	57
371	CYCLOSPORIN A AS THE INITIAL IMMUNOSUPPRESSIVE AGENT FOR CANINE LUNG TRANSPLANTATION. Transplantation, 1982, 34, 372-375.	0.5	18
372	INFLUENCE OF CADAVER DONOR AGE ON THE SUCCESS OF KIDNEY TRANSPLANTS. Transplantation, 1981, 32, 532-534.	0.5	39
373	Total or Near Total Pancreatectomy and Islet Autotransplantation for Treatment of Chronic Pancreatitis. Annals of Surgery, 1980, 192, 526-542.	2.1	160
374	Prolongation of mouse and rat pancreatic islet cell allografts by adenosine deaminase inhibitors and adenine arabinoside. Journal of Surgical Research, 1980, 28, 44-48.	0.8	11
375	Amelioration of streptozotocin-induced diabetes in rats: Effect of islet isografts on plasma lipids and other metabolic abnormalities. Metabolism: Clinical and Experimental, 1979, 28, 489-494.	1.5	11
376	Surgical Problems in Immunodeficient and Immunosuppressed Children. Surgical Clinics of North America, 1979, 59, 213-221.	0.5	4
377	DL-ethionine Treatment of Adult Pancreatic Donors Amelioration of Diabetes in Multiple Recipients with Tissue From a Single Donor. Annals of Surgery, 1979, 189, 248-256.	2.1	22
378	EFFECT OF AN ADENOSINE DEAMINASE INHIBITOR ON SURVIVAL OF MOUSE PANCREATIC ISLET ALLOGRAFTS. Transplantation, 1979, 27, 355-357.	0.5	10

#	ARTICLE	IF	CITATIONS
379	ENCEPHALOMYOCARDITIS VIRUS-INDUCED DIABETES MELLITUS TREATED BY ISLET TRANSPLANTATION. Transplantation, 1979, 27, 200-202.	0.5	6
380	Pancreatic Islet Cell Transplantation. Surgical Clinics of North America, 1978, 58, 365-382.	0.5	191
381	SYNERGISTIC EFFECT OF DONOR-SPECIFIC SOLUBLE MEMBRANE ANTIGEN INJECTION AND ANTITHYMOCYTE SERUM ADMINISTRATION ON THE SURVIVAL OF ISLET ALLOGRAFTS IN RATS. Transplantation, 1978, 25, 336-338.	0.5	6
382	Autotransplantation of Pancreatic Fragments to the Portal Vein and Spleen of Totally Pancreatectomized Dogs. Annals of Surgery, 1978, 187, 79-86.	2.1	47
383	Pseudorejection. Annals of Surgery, 1977, 186, 51-59.	2.1	27
384	LIVER CYSTS IN STREPTOZOTOCIN-TREATED RATS. Transplantation, 1977, 24, 162-163.	0.5	4
385	When Should the Third Renal Transplant Rejection Episode be Treated?. Annals of Surgery, 1977, 186, 104-110.	2.1	4
386	A MOUSE MODEL OF ISLET TRANSPLANTATION USING NEONATAL DONORS. Transplantation, 1977, 24, 389-392.	0.5	7
387	PORTAL VERSUS SYSTEMIC TRANSPLANTATION OF DISPERSED NEONATAL PANCREAS. Transplantation, 1977, 24, 333-337.	0.5	24
388	Islet transplantation using neonatal rat pancreata: Quantitative studies. Journal of Surgical Research, 1976, 20, 143-147.	0.8	24
389	Post-transplant malignant lymphoma. American Journal of Medicine, 1976, 61, 716-720.	0.6	87
390	IMMUNOPATHOLOGICAL STUDIES OF THE RUPTURED HUMAN RENAL ALLOGRAFT. Transplantation, 1976, 22, 420-426.	0.5	20
391	Seven Years½ Experience with Antilymphoblast Globulin for Renal Transplantation From Cadaver Donors. Annals of Surgery, 1976, 184, 352-368.	2.1	92
392	Successful renal transplantation in patients with prior history of malignancy. American Journal of Medicine, 1975, 59, 791-795.	0.6	18
393	Lethal complications of bilateral nephrectomy and splenectomy in hemodialyzed patients. American Journal of Surgery, 1975, 129, 616-620.	0.9	51
394	Increased Serum Creatinine Resulting from Hyperglycemia, Mimicking Transplant Rejection. Annals of Internal Medicine, 1975, 83, 519.	2.0	8